African Journals Online
metadata only
In silico profiling, molecular docking, and RMSD prediction of novel chalcone-schiff base hybrid derivatives as HDAC2 inhibitors
Purpose: To investigate the pharmacokinetic properties and binding affinities of a series of chalcone-Schiff base hybrid derivatives.Methods: The pharmacokinetic properties and binding affinities of a series of chalcone-Schiff base hybrid derivatives (compounds I - XI) for HDAC2 enzyme were evaluate
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Official Review · ICLR 2025#787137
- Docking and Machine Learning approaches to explore new scaffolds for molecules of therapeutic interest. (Approches de docking et de Machine Learning pour l'exploration de nouveaux « scaffolds » lors de la recherche de molécules d'intérêt thérapeutique).#489534
- Open-Source Molecular Docking and AI-Augmented Structure-Based Drug Design: Current Workflows, Challenges, and Opportunities.#9333
- In Silico Identification of Natural-Product Aromatase (CYP19A1) Inhibitors via Integrated Molecular Docking and QSAR Modelling.#636344
- Quinazolinone–hydroxamate derivatives as potential HDAC8 inhibitors: An integrated docking, ADME, DFT, and molecular dynamics study#466997
Record · ID 990847
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive